OBJECTIVE: To examine outcomes at age 4.5 years and compare to earlier ages in children with fetal antiepileptic drug (AED) exposure. METHODS: The NEAD Study is an ongoing prospective observational multicenter study, which enrolled pregnant women with epilepsy on AED monotherapy (1999-2004) to determine if differential long-term neurodevelopmental effects exist across 4 commonly used AEDs (carbamazepine, lamotrigine, phenytoin, or valproate). The primary outcome is IQ at 6 years of age. Planned analyses were conducted using Bayley Scales of Infant Development (BSID at age 2) and Differential Ability Scale (IQ at ages 3 and 4.5). RESULTS: Multivariate intent-to-treat (n = 310) and completer (n = 209) analyses of age 4.5 IQ revealed significant effects for AED group. IQ for children exposed to valproate was lower than each other AED. Adjusted means (95% confidence intervals) were carbamazepine 106 (102-109), lamotrigine 106 (102-109), phenytoin 105 (102-109), valproate 96 (91-100). IQ was negatively associated with valproate dose, but not other AEDs. Maternal IQ correlated with child IQ for children exposed to the other AEDs, but not valproate. Age 4.5 IQ correlated with age 2 BSID and age 3 IQ. Frequency of marked intellectual impairment diminished with age except for valproate (10% with IQ <70 at 4.5 years). Verbal abilities were impaired for all 4 AED groups compared to nonverbal skills. CONCLUSIONS: Adverse cognitive effects of fetal valproate exposure persist to 4.5 years and are related to performances at earlier ages. Verbal abilities may be impaired by commonly used AEDs. Additional research is needed.
OBJECTIVE: To examine outcomes at age 4.5 years and compare to earlier ages in children with fetal antiepileptic drug (AED) exposure. METHODS: The NEAD Study is an ongoing prospective observational multicenter study, which enrolled pregnant women with epilepsy on AED monotherapy (1999-2004) to determine if differential long-term neurodevelopmental effects exist across 4 commonly used AEDs (carbamazepine, lamotrigine, phenytoin, or valproate). The primary outcome is IQ at 6 years of age. Planned analyses were conducted using Bayley Scales of Infant Development (BSID at age 2) and Differential Ability Scale (IQ at ages 3 and 4.5). RESULTS: Multivariate intent-to-treat (n = 310) and completer (n = 209) analyses of age 4.5 IQ revealed significant effects for AED group. IQ for children exposed to valproate was lower than each other AED. Adjusted means (95% confidence intervals) were carbamazepine 106 (102-109), lamotrigine 106 (102-109), phenytoin 105 (102-109), valproate 96 (91-100). IQ was negatively associated with valproate dose, but not other AEDs. Maternal IQ correlated with child IQ for children exposed to the other AEDs, but not valproate. Age 4.5 IQ correlated with age 2 BSID and age 3 IQ. Frequency of marked intellectual impairment diminished with age except for valproate (10% with IQ <70 at 4.5 years). Verbal abilities were impaired for all 4 AED groups compared to nonverbal skills. CONCLUSIONS: Adverse cognitive effects of fetal valproate exposure persist to 4.5 years and are related to performances at earlier ages. Verbal abilities may be impaired by commonly used AEDs. Additional research is needed.
Authors: Petra Bittigau; Marco Sifringer; Kerstin Genz; Ellen Reith; Dana Pospischil; Suresh Govindarajalu; Mark Dzietko; Stefanie Pesditschek; Ingrid Mai; Krikor Dikranian; John W Olney; Chrysanthy Ikonomidou Journal: Proc Natl Acad Sci U S A Date: 2002-11-04 Impact factor: 11.205
Authors: Torbjörn Tomson; Dina Battino; Erminio Bonizzoni; John Craig; Dick Lindhout; Anne Sabers; Emilio Perucca; Frank Vajda Journal: Lancet Neurol Date: 2011-06-05 Impact factor: 44.182
Authors: C Ikonomidou; P Bittigau; M J Ishimaru; D F Wozniak; C Koch; K Genz; M T Price; V Stefovska; F Hörster; T Tenkova; K Dikranian; J W Olney Journal: Science Date: 2000-02-11 Impact factor: 47.728
Authors: N Adab; U Kini; J Vinten; J Ayres; G Baker; J Clayton-Smith; H Coyle; A Fryer; J Gorry; J Gregg; G Mawer; P Nicolaides; L Pickering; L Tunnicliffe; D W Chadwick Journal: J Neurol Neurosurg Psychiatry Date: 2004-11 Impact factor: 10.154
Authors: E Gaily; E Kantola-Sorsa; V Hiilesmaa; M Isoaho; R Matila; M Kotila; T Nylund; A Bardy; E Kaaja; M-L Granström Journal: Neurology Date: 2004-01-13 Impact factor: 9.910
Authors: Chrysanthy Ikonomidou; George Kirvassilis; Brant S Swiney; Sophie H Wang; Jacob N Huffman; Sasha L Williams; Kobe Masuoka; Saverio Capuano; Kevin R Brunner; Kristin Crosno; Heather S Simmons; Andres F Mejia; Christopher A Turski; Ansgar Brambrink; Kevin K Noguchi Journal: Neurobiol Dis Date: 2019-06-05 Impact factor: 5.996
Authors: Morris J Cohen; Kimford J Meador; Nancy Browning; Ryan May; Gus A Baker; Jill Clayton-Smith; Laura A Kalayjian; Andres Kanner; Joyce D Liporace; Page B Pennell; Michael Privitera; David W Loring Journal: Epilepsy Behav Date: 2013-09-05 Impact factor: 2.937
Authors: Kimford J Meador; Gus A Baker; Nancy Browning; Morris J Cohen; Rebecca L Bromley; Jill Clayton-Smith; Laura A Kalayjian; Andres Kanner; Joyce D Liporace; Page B Pennell; Michael Privitera; David W Loring Journal: Lancet Neurol Date: 2013-01-23 Impact factor: 44.182
Authors: Gyri Veiby; Anne K Daltveit; Synnve Schjølberg; Camilla Stoltenberg; Anne-Siri Øyen; Stein E Vollset; Bernt A Engelsen; Nils E Gilhus Journal: Epilepsia Date: 2013-07-19 Impact factor: 5.864